Stock listing
NASDAQ:TOCA Tocagen Inc Stock
Follow Tocagen Inc into a list and get an email when it puts out news.
Delisted NASDAQ:TOCA no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:TOCA
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest deck · Jul 9, 2026
Forte Biosciences — Technical Presentation (July 2026)
Technical · 21 slides
Tocagen Inc on 6ix
- Decks
- 23 decks · latest Jul 9, 2026
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Forte Biosciences — Technical Presentation (July 2026) | Technical | 21 slides | Jul 9, 2026 |
| Forte Biosciences — Corporate Update (August 2025) | Corporate update | 68 slides | Aug 14, 2025 |
| Forte Biosciences — Technical Presentation (June 2025) | Technical | 33 slides | Jun 23, 2025 |
| Forte Biosciences — Investor Presentation (June 2025) | Investor deck | 66 slides | Jun 23, 2025 |
| Forte Biosciences — Investor Presentation (December 2024) | Investor deck | 60 slides | Dec 3, 2024 |
| Forte Biosciences — Investor Presentation (December 2024) | Investor deck | 49 slides | Dec 3, 2024 |
| Forte Biosciences — Investor Presentation (August 2024) | Investor deck | 46 slides | Aug 14, 2024 |
| Forte Biosciences — Investor Presentation (May 2024) | Investor deck | 32 slides | May 13, 2024 |
| Forte Biosciences — Investor Presentation (March 2024) | Investor deck | 32 slides | Mar 18, 2024 |
| Forte Biosciences — Proxy Contest (September 2023) | Proxy contest | 40 slides | Sep 1, 2023 |
All 23 decks
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Faheem Hasnain Other companies: Aspen Neuroscience, Inc. (Aspen Executive Chairman · Since at least Nov 2, 2026); Gossamer Bio, Inc. (Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past) | Director · Apr 12, 2017 – Oct 4, 2019 · Past |
| Franklin Berger Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026); Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 25, 2019); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Kineta Inc. (Director · Jun 27, 2019 – Jun 29, 2020 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Five Prime Therapeutics Inc (Director · Jun 10, 2019 – Apr 16, 2021 · Past); Immune Design Corp (Director · Apr 2, 2019 – Apr 2, 2019 · Past) | Director · May 29, 2019 – Oct 4, 2019 · Past |
| Lori Kunkel Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); ORIC Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2020); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 19, 2025 · Past); Curis, Inc. (Director · Jan 22, 2018 – Jan 31, 2022 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past) | Director · Jun 21, 2018 – Oct 4, 2019 · Past |
| Paul Schimmel Other companies: aTyr Pharma, Inc. (Director · Since at least May 6, 2015); Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Repligen Corporation (Director · Aug 11, 2006 – Jun 14, 2007 · Past); Alkermes plc (Director · Mar 2, 2006 – Jun 15, 2007 · Past) | Director · Apr 12, 2017 – Oct 4, 2019 · Past |
| Mark Foletta Other companies: Enanta Pharmaceuticals, Inc. (Director · Since at least Jun 29, 2020); AMN Healthcare Services Inc (Director · Since at least Nov 27, 2017); DexCom, Inc. (Director · Since at least Nov 27, 2017); Regulus Therapeutics Inc (Director · Dec 4, 2017 – Dec 4, 2017 · Past) | EVP & Chief Financial Officer · Dec 8, 2017 – Oct 4, 2019 · Past |
| Fairooz Kabbinavar Other companies: Cardiff Oncology, Inc. (Chief Medical Officer · Jan 30, 2023 – Mar 11, 2025 · Past) | SVP Clinical Development · Apr 15, 2019 – Oct 4, 2019 · Past |
| Douglas Jolly | EVP, Research & Pharm Devel · Apr 12, 2017 – Oct 4, 2019 · Past |
| Martin J Duvall | Chief Executive Officer, Director · Dec 8, 2017 – Oct 4, 2019 · Past |
Log in to ask 6ix AI your own questions about Tocagen Inc.